The WACC of Hikma Pharmaceuticals PLC (HIK.L) is 8.7%.
| Range | Selected | |
| Cost of equity | 8.50% - 10.80% | 9.65% |
| Tax rate | 21.90% - 22.90% | 22.40% |
| Cost of debt | 5.10% - 6.70% | 5.90% |
| WACC | 7.7% - 9.8% | 8.7% |
| Category | Low | High |
| Long-term bond rate | 4.0% | 4.5% |
| Equity market risk premium | 6.0% | 7.0% |
| Adjusted beta | 0.75 | 0.83 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 8.50% | 10.80% |
| Tax rate | 21.90% | 22.90% |
| Debt/Equity ratio | 0.22 | 0.22 |
| Cost of debt | 5.10% | 6.70% |
| After-tax WACC | 7.7% | 9.8% |
| Selected WACC | 8.7% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for HIK.L:
cost_of_equity (9.65%) = risk_free_rate (4.25%) + equity_risk_premium (6.50%) * adjusted_beta (0.75) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.